Bavarian Nordic delivers 440,000 MPOX vaccine in alarm level

Bavarian Nordic delivers 440,000 MPOX vaccine in alarm level

The Danish-German pharmaceutical company Bavarian Nordic has received an important order that includes the delivery of 440,000 cans of his MPOX vaccine. This step takes place in the context of a recently proclaimed health.

The decision to make an emergency was announced by the World Health Organization (WHO), which has expressed a concern about the rapid spread of this sub -variant. The WHO also called for an increase in production capacities for MPOX vaccines in order to meet the increasing threat. Bavarian Nordic has made it clear that this new order was already taken into account in its plans for the year, which means that the company's ability to react to the global health crisis is not impaired.

The role of the WHO

The WHO is an important concern to prevent the spread of MPOX, especially in view of the fact that the disease can be transmitted from both animals and from person to person. The most common symptoms include rock -like pustules, fever and general body pain. Experts are particularly worried about the sub -variant 1b, which is common in the Democratic Republic of Congo and in other African countries such as Kenya, Rwanda and Uganda.

There are currently two vaccines available for combating MPOX: MVA BN by Bavarian Nordic and another vaccine developed on behalf of the Japanese government, known as LC16. This health emergency shows how pressing the situation in the world health landscape is and how quickly new challenges can arise.

The need to expand the production capacities has also attracted the attention of other countries that have to prepare for this potential threat. It is crucial that the global community works together to prevent further propagation and to offer people effective vaccination protection measures.

Additional information about the MPOX

The word "MPOX" has been heard often lately, and many people wonder what exactly it means. This disease, previously known as monkey quits, is primarily transferred between people, which also includes sexual encounters. The current symptoms can not only be very uncomfortable, but also lead to serious health complications, especially for endangered groups of people.

The WHO has already raised the alarm and emphasizes that the time for preventive measures and vaccination programs is now pressing. The reports about new infection cases are increasingly worrying, especially in certain hotspots, which requires the rapid reaction of the responsible health authorities.

Vaccination is an effective means of spreading the disease, and with the new mandate of Bavarian Nordic, another step to combat MPOX is taken.

insight into the health challenges

Bavarian Nordic has not only developed the MPOX vaccine (formerly monkeys), but also gained extensive experience in vaccine production in the past. The company is known for its innovative vaccine solutions that address global health problems, including vaccines against smallpox and other virus infections.

background information on MPOX

mpox, formerly known as monkeys, is a viral zoonosis caused by the MPOX virus. It is a disease that mainly occurs in certain regions of Africa, but has also been widespread beyond the African continent in recent years. The disease often manifests itself in the form of pustules, fever and body aches and can have serious health consequences. The transfer is made by animals to humans, but is also possible through direct contact between people. Above all, close social interactions are a source of transmission.

The health authorities and the WHO deal intensively with the control and combat of MPOX, especially after the disease has occurred in several non -endemic countries. The need for effective vaccines has thus proven to be urgent, especially against the background of the worrying new sub -variants of the virus.

Current statistical data for the distribution of MPOX

The WHO has recorded an increase in cases of MPOX in different countries in the last reports. According to a current report, there were over 80,000 confirmed cases worldwide in 2022. The majority of these cases occurred in countries where the disease was not previously known. It is particularly noteworthy that most of the subjects are under 50 years old and that the transmission often takes place in communities or social networks with close contact.

The WHO has called on the countries to implement vaccination strategies and information campaigns in order to contain the spread of the virus. The implementation of vaccination programs that focus on high -risk groups is one of the recommended interventions.

It is important for the public to be informed about MPOX's symptoms and transmission paths in order to counteract the spread of the disease and to protect endangered groups. The WHO and other health organizations offer resources to educate people about MPOX and promote preventive measures. Further information is available on the website of World Health Organization